An interventional study of Medtronic 780G System and Continuous Glucose Monitoring in Chronic Kidney Diseases and Diabetes Mellitus, sponsored by Imperial College London. Recruiting at 1 site in United Kingdom. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-01-08.
Sponsored by Imperial College London · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 230 studies in Renal Insufficiency, Chronic with a site in United Kingdom — 32 open to participants now, 50 under way, 17 of them phase 3. Renal Insufficiency, Chronic · United Kingdom.
Among the 230 studies in Renal Insufficiency, Chronic with a site in United Kingdom, this one is the 146th largest by planned enrollment of the 159 interventional ones that give a count, is one of 11 that started in 2025, is one of 31 with no phase, reaches primary completion later than 13 of the 49 other live ones, and was the 204th registered.
3,098 studies on the registry are indexed under Renal Insufficiency, Chronic; 700 are open to participants now.
Browse Renal Insufficiency, Chronic studies →32 of the 230 studies in Renal Insufficiency, Chronic with a site in United Kingdom are open now. Recruiting first, the newest first:
Imperial College London · Sites in United Kingdom
Ages 18+
AstraZeneca · Sites in United Kingdom, United States, Argentina and 24 more countries
Ages 18–99
AstraZeneca · Sites in United Kingdom, United States, Argentina and 34 more countries
Ages 18+
Vifor Fresenius Medical Care Renal Pharma · Sites in United Kingdom, China, Greece and 4 more countries
Ages 12–18
King's College London · Sites in United Kingdom
Ages 10–25 · Healthy volunteers
A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →
Of the 434 Renal Insufficiency, Chronic studies recruiting now, 245 (56%) set no upper age limit and 110 (25%) stop at 75 or younger; 43 take children under 18; 80 take healthy volunteers.
This study: 18 Years to 70 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
230 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 13 · Phase 2 39 · Phase 3 69 · Phase 4 11
First in 2003; this study’s year is marked. 11 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 12 is below the median of 73 across 2,164 interventional studies indexed under Renal Insufficiency, Chronic.
Median enrollment 139 across the 159 interventional studies, 119 across the 71 observational. Of the 155 that completed or were terminated, 72 (46%) have results posted.
This tab as a report to print or save as PDF → With an account.
120 of 230 have an industry lead sponsor. The 10 most frequent:
Imperial College London is the lead sponsor of 844 studies on the registry; 181 are open to participants now.
Of its 9 completed or terminated interventional studies of FDA-regulated products, 6 (67%) have results posted.
Imperial College London has 8 studies filed under Renal Insufficiency, Chronic — fewer than ten, so there is no comparison to draw.
17 of the studies in Renal Insufficiency, Chronic with a site in United Kingdom that are under way reach primary completion within a year, 6 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06531824Phase 3Boehringer IngelheimEASi-KIDNEY™ (The Studies of Heart & Kidney Protection With BI 690517 in Combination With Empagliflozin) | 2026-12-31 |
| NCT05196035Phase 3BayerA Study to Learn More About How Well the Study Treatment Finerenone Works, How Safe it is, How it Moves Into, Through, and Out of the Body, and the Effects it Has on the Body When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker in Children With Chronic Kidney Disease and Proteinuria | 2027-04-10 |
| NCT07107945Phase 3Boehringer IngelheimA Study to Find Out How EMPAgliflozin is Tolerated and if it Helps Children and Adolescents With Chronic KIDNEY Disease (EMPA-KIDNEY® Kids) | 2027-04-16 |
| NCT03969329Phase 3AmgenA Phase 3 Study of Etelcalcetide in Children With Secondary Hyperparathyroidism Receiving Hemodialysis | 2027-06-30 |
| NCT05852938Phase 3Novartis PharmaceuticalsA Study of Zigakibart in Adults With IgA Nephropathy | 2027-08-10 |
Add all 17 to your calendar (.ics) → With an account.
Among the 230 studies in Renal Insufficiency, Chronic with a site in United Kingdom, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Diabetes is the leading cause of kidney failure in the UK. Many people with diabetes and advanced kidney failure inject themselves with insulin and do finger-prick blood glucose tests. Managing diabetes in people with advanced kidney disease is hard, with fluctuating glucose levels and an increased risk of unsafe low glucose levels.
There are currently continuous glucose monitors (CGM), which allow people to monitor glucose without painful fingerprick tests. CGM can be combined with insulin pumps to create automated insulin delivery systems (AID) that deliver insulin automatically to control glucose. AID systems are currently used in people with type 1 diabetes, but they are not used in people with type 2 diabetes. There is little information on how these systems might help people with diabetes and advanced kidney failure and on dialysis.
This study will investigate whether automated insulin delivery can improve glucose levels and quality of life in people with diabetes treated with more than one insulin injection with advanced kidney failure and/or undergoing regular dialysis treatment. This study will be a feasibility study conducted in a single centre (Imperial College, London) and be of a cross-over design. The study will aim to complete 12 people. Participants will wear a glucose sensor at the start. In random order, half will start AID followed by the usual treatment, while the other half will start the usual treatment followed by AID treatment. The duration of each treatment stage is eight weeks. The study will last about 22 weeks for each participant. Investigators will compare the glucose levels in the AID group with the usual care group to see if there is a difference. Questionnaires and interviews will help us understand participants' experiences. Investigators will carefully monitor the safety of participants.
This will be a single-centre, prospective, open-label, two-stage, randomized crossover study comparing automated subcutaneous insulin delivery (AID), also known as Hybrid Closed Loop (HCL) therapy using the 780G system with usual insulin therapy plus continuous glucose monitoring (CGM) in people with type 1 and type 2 diabetes complicated by advanced renal disease and managed with insulin. The study will be conducted at Imperial College Healthcare NHS Trust.
Duration of each treatment arm is 8 weeks
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Device: Medtronic 780G System
Device: Continuous Glucose Monitoring
Automated insulin delivery using Medtronic 780G system
Usual care with continuous glucose monitoring
Percent time in sensor glucose target range (3.9-10.0 mmol/L)
Percent time in sensor glucose target range (3.9-10.0 mmol/L) with Automated Insulin Delivery (AID) versus Usual Care measured during the final 3 weeks of each study stage.
Time frame: 3 weeks
Percent time in sensor glucose target range (<3.0 mmol/L)
Percent time in sensor glucose target range (\<3.0 mmol/L) with AID versus Usual Care, measured during the final 3 weeks of each study stage
Time frame: 3 weeks
Percent time in sensor glucose target range (<3.9 mmol/L)
Percent time in sensor glucose target range (\<3.9 mmol/L) with AID versus Usual Care, measured during the final 3 weeks of each study stage
Time frame: 3 weeks
Percent time in sensor glucose target range (>10 mmol/L)
Percent time in sensor glucose target range (\<10 mmol/L) with AID versus Usual Care, measured during the final 3 weeks of each study stage
Time frame: 3 weeks
Percent time in sensor glucose target range (<2.8 mmol/L)
Percent time in sensor glucose target range (\<2.8 mmol/L) with AID versus Usual Care, measured during the final 3 weeks of each study stage
Time frame: 3 weeks
Percent time in sensor glucose target range (<3.3 mmol/L)
Percent time in sensor glucose target range (\<3.3 mmol/L) with AID versus Usual Care, measured during the final 3 weeks of each study stage
Time frame: 3 weeks
Percent time in sensor glucose target range (>13.9 mmol/L)
Percent time in sensor glucose target range (\<13.9 mmol/L) with AID versus Usual Care, measured during the final 3 weeks of each study stage
Time frame: 3 weeks
Percent time in sensor glucose target range (>16.7 mmol/L)
Percent time in sensor glucose target range (\<16.7 mmol/L) with AID versus Usual Care, measured during the final 3 weeks of each study stage
Time frame: 3 weeks
Percent time in sensor glucose target range (3.9-7.8 mmol/L)
Percent time in sensor glucose target range (3.9-7.8 mmol/L) with AID versus Usual Care, measured during the final 3 weeks of each study stage
Time frame: 3 weeks
Mean sensor glucose
Mean sensor glucose with AID versus Usual Care, measured during the final 3 weeks of each study stage
Time frame: 3 weeks
Standard deviation and coefficient of variation of sensor glucose
Standard deviation and coefficient of variation of sensor glucose with AID versus Usual Care, measured during the final 3 weeks of each study stage
Time frame: 3 weeks
The Diabetes Treatment Satisfaction Questionnaire status
The Diabetes Treatment Satisfaction Questionnaire status with AID versus Usual Care
Time frame: 8 weeks
Hypoglycaemia Fear Survey
Hypoglycaemia Fear Survey with AID versus Usual Care
Time frame: 8 weeks
EQ-5D-5L
EQ-5D-5L with AID versus Usual Care
Time frame: 8 weeks
Episodes of CGM time in <3.0mmol/L range lasting >15minutes
Episodes of CGM time in \<3.0mmol/L range lasting \>15minutes with AID versus Usual Care
Time frame: 3 weeks
Number of hospital admissions with diabetic ketoacidosis or hyperosmolar non-ketotic hyperglycaemia
Number of hospital admissions with diabetic ketoacidosis or hyperosmolar non-ketotic hyperglycaemia with AID versus Usual Care
Time frame: 8 weeks
Number of hospitalised and non-hospitalised patients with severe hypoglycaemia
Number of hospitalised and non-hospitalised patients with severe hypoglycaemia with AID versus Usual Care
Time frame: 8 weeks
Plan to share: No — No plans to share IPD
Started Nov 2025 (actual). Primary completion is estimated for Dec 2026, 13 months after the start.
Of 580 non-industry interventional studies with no phase under Renal Insufficiency, Chronic, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 45. This study's planned 13 months is below that.
Counting every sponsor, half of 620 studies reached it within 23 months; a quarter within 10 and three quarters within 45.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Renal Insufficiency, Chronic →